NeOnc Technologies Holdings will present clinical data from its brain cancer drug programs NEO100 and NEO212 at the Society for Neuro-Oncology Annual Meeting in November 2026. NEO100 is an intranasal therapy targeting recurrent astrocytoma, while NEO212 is an oral drug being tested for glioblastoma and brain metastases. These presentations highlight progress in developing new treatments for central nervous system cancers. Both drugs remain investigational and are in early clinical stages, with further studies needed to confirm safety and efficacy.
NeOnc Technologies' brain cancer drug programs are the subject, with Pluang market data as context. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced US health-sector stocks, 82 rose and 47 fell today. Notable movers include DNA (Ginkgo Bioworks Holdings Inc) at USD 11.79 with a +4.99% change, ALMS (Alumis Inc. Common Stock) at USD 7.04 with +4.45%, and HRTX (Heron Therapeutics Inc) at USD 0.29 with +4.43%.
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
